The presence of a somatic RET mutation correlates with a worse outcome for MTC patients, not only because of the higher probability of persistent disease, but also because of a lower survival rate in a long-term follow up [53,54]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.